中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 3
Mar.  2016
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2016  >  32(3): 484-487

Effects of HBV X protein on expression and promoter methylation of p16 tumor suppressor gene

DOI: 10.3969/j.issn.1001-5256.2016.03.017

  • Department of Infectious Diseases, Henan Provincial People′s Hospital

Research funding:

 

  • Published Date: 2016-03-20
    Abstract
  • Objective To explore the effects of hepatitis B virus X protein( HBx) on the expression and promoter methylation of the p16 tumor suppressor gene,and to investigate the epigenetic role of HBx in the development and progression of hepatitis B virus( HBV)- associated hepatocellular carcinomas( HCC). Methods Experiments were performed in the human hepatoblastoma cell line Hep G2,Hep G2 cells expressing green fluorescent protein( Hep G2 / GFP),and Hep G2 cells stably expressing GFP- HBx fusion protein( Hep G2 / GFP- HBx).Western blot was used to determine the expression levels of the p16 protein in Hep G2 cells,Hep G2 / GFP cells,and Hep G2 / GFP- HBx cells. Hep G2 / GFP- HBx cells were treated with a universal inhibitor of DNA methyltransferase( DNMT),5- aza- 2'- deoxycytidine( 5-aza- 2'- d C). Methylation- specific polymerase chain reaction( MSP) was used to determine the promoter methylation of the p16 tumor suppressor gene in Hep G2 cells,Hep G2 / GFP cells,and Hep G2 / GFP- HBx cells treated with or without 5- aza- 2'- d C. Multiple- group comparison was made by analysis of variance. Results According to the results of Western blot,Hep G2 / GFP- HBx cells had a significantly lower expression level of the p16 protein than Hep G2 cells and Hep G2 / GFP cells( P = 0. 0007; P = 0. 0014); there was no significant difference in the expression level of the p16 protein between Hep G2 / GFP and Hep G2 cells( P > 0. 05). The MSP assay revealed partial Cp G methylation in the p16 promoter region in Hep G2 / GFP- HBx cells. No promoter methylation was detected in Hep G2 cells or Hep G2 / GFP cells. Non- methylation in the p16 promoter region was restored in Hep G2 / GFP- HBx cells treated with 5- aza- 2'- d C. Conclusion In the hepatoblastoma cell line,HBx down- regulates the expression of the p16 tumor suppressor gene by inducing methylation in its promoter region. The DNMT inhibitor,5- aza- 2'- d C,restores non- methylation in the p16 promoter region. The reversible modification provides new insights for the treatment and prevention of HBV- associated HCC.

     

    • FullText(HTML)
    • References(17)
  • [1]FARES N,PERON JM.Epidemiology,natural history,and risk factors of hepatocellular carcinoma[J].Rev Prat,2013,63(2):216-217,220-222.
    [2]KEW MC.Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma[J].J Gastroenterol Hepatol,2011,26(Suppl 1):144-152.
    [3]MOTAVAF M,SAFARI S,SAFFARI JM,et al.Hepatitis B virus-induced hepatocellular carcinoma:the role of the virus x protein[J].Acta Virol,2013,57(4):389-396.
    [4]DONG Y,WANG A.Aberrant DNA methylation in hepatocellular carcinoma tumor suppression(Review)[J].Oncol Lett,2014,8(3):963-968.
    [5]LEE H,SOHN JB,KIM SS,et al.DNA methyltransferase inhibitor assay system based on the HBx-induced DNA methylation of Ecadherin[J].Biochem Biophys Res Commun,2013,438(3):540-545.
    [6]KOTAKE Y,NAEMURA M,MURASAKI C,et al.Transcriptional regulation of the p16 tumor suppressor gene[J].Anticancer Res,2015,35(8):4397-4401.
    [7]FERNANDEZ AF,ESTELLER M.Viral epigenomes in human tumorigenesis[J].Oncogene,2010,29(10):1405-1420.
    [8]RONGRUI L,NA H,ZONGFANG L,et al.Epigenetic mechanism involved in the HBV/HCV-related hepatocellular carcinoma tumorigenesis[J].Curr Pharm Des,2014,20(11):1715-1725.
    [9]KAUR P,PALIWAL A,DURANTEL D,et al.DNA methylation of hepatitis B virus(HBV)genome associated with the development of hepatocellular carcinoma and occult HBV infection[J].J Infect Dis,2010,202(5):700-704.
    [10]CSEPREGI A,EBERT M,RCKEN C,et al.Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma[J].BMC Cancer,2010,10(1):317.
    [11]ANZOLA M,CUEVAS N,LOPEZ MARTINEZ M,et al.p16INK4A gene alterations are not a prognostic indicator for survival in patients with hepatocellular carcinoma undergoing curative hepatectomy[J].J Gastroenterol Hepatol,2004,19(4):397-405.
    [12]MATSUDA Y,ICHIDA T,MATSUZAWA J,et al.p16(INK4)is inactivated by extensive Cp G methylation in human hepatocellular carcinoma[J].Gastroenterology,1999,116(2):394-400.
    [13]JICAI Z,ZONGTAO Y,JUN L,et al.Persistent infection of hepatitis B virus is involved in high rate of p16 methylation in hepatocellular carcinoma[J].Mol Carcinog,2006,45(7):530-536.
    [14]BHAGAT R,KUMAR SS,VADERHOBLI S,et al.Epigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma[J].Tumour Biol,2014,35(9):9069-9078.
    [15]LEE MH,NA H,NA TY,et al.Epigenetic control of metastasisassociated protein 1 gene expression by hepatitis B virus X protein during hepatocarcinogenesis[J].Oncogenesis,2014,3:e88.
    [16]PROTZER U.Hepatitis:Epigenetic control of HBV by HBx proteinreleasing the break?[J].Nat Rev Gastroenterol Hepatol,2015,12(10):558-559.
    [17]VALDESPINO-GOMEZ VM,VALDESPINO-CASTILLO VE.Targeted epigenetic therapy of cancer.Achievements and perspectives[J].Cir Cir,2012,80(5):470-480.
    • Relative Articles

  • Relative Articles

    [1]Huajie XIE, Kai CHANG, Yanyan WANG, Wanlin NA, Huan CAI, Xia LIU, Zhongyong JIANG, Zonghai HU, Yuan LIU. Characteristics of mitochondrial translational initiation factor 2 gene methylation and its association with the development of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2025, 41(2): 284-291. doi: 10.12449/JCH250214
    [2]Yuwen ZENG, Fangyong ZHANG, Guoqian TAN, Fan WU. Expression and biological role of the neutral cholesterol ester hydrolase 1 gene in liver cancer tissue and cell lines[J]. Journal of Clinical Hepatology, 2021, 37(8): 1867-1872. doi: 10.3969/j.issn.1001-5256.2021.08.023
    [3]Zhou HuiFang, Wei HeRu, Ma ShiChao, Zhang ChaoQun, Wang JunPing, Yang XinYing, Xie Ying, Sun DianXing. Construction of the eukaryotic expression vector of collagen triple helix repeat containing 1 gene and its association with microRNA-30b[J]. Journal of Clinical Hepatology, 2020, 36(2): 377-380. doi: 10.3969/j.issn.1001-5256.2020.02.029
    [4]Zhou Yan, Ning Bo. Application of abnormal cell-free DNA methylation in pancreatic juice in the early diagnosis of pancreatic cancer[J]. Journal of Clinical Hepatology, 2020, 36(9): 2145-2148. doi: 10.3969/j.issn.1001-5256.2020.09.054
    [5]Xu Chu, Zhang PingAn. Influence of hepatitis C virus on the expression of lipid metabolism indices[J]. Journal of Clinical Hepatology, 2019, 35(5): 987-991. doi: 10.3969/j.issn.1001-5256.2019.05.011
    [6]Liu Tao, Xu QiuLing. Spleen-strengthening and dampness-removing therapy exerts a therapeutic effect on nonalcoholic fatty liver disease by regulating hepatic MTP promoter methylation[J]. Journal of Clinical Hepatology, 2019, 35(3): 661-664. doi: 10.3969/j.issn.1001-5256.2019.03.047
    [7]Li KeXin, Zang MengYa, Wang DongMei, He Huan, Wang YuTing, Qu ChunFeng. Effect of interleukin-17A on stemness of hepatoma cell lines[J]. Journal of Clinical Hepatology, 2017, 33(6): 1131-1136. doi: 10.3969/j.issn.1001-5256.2017.06.023
    [8]Shi JuanJuan, Yang Ning, Zhang Xin, Wu FengPing, Li Mei, Gao Ning, Jia XiaoLi, Zhai Song, Dang ShuangSuo. Effect of prohibitin on hepatitis C virus replication[J]. Journal of Clinical Hepatology, 2016, 32(9): 1729-1733. doi: 10.3969/j.issn.1001-5256.2016.09.019
    [9]Cheng KangWen, Li Qi, Zhan YongQiang, Wang ChengYou, Wang GuiHe, Ni Yong, Zhu BaoHe, Deng XueSong. Effects of 5-fluorouracil on biological characteristics and drug resistance mechanisms of liver cancer cell line PLC/RAF/5[J]. Journal of Clinical Hepatology, 2015, 31(9): 1458-1463. doi: 10.3969/j.issn.1001-5256.2015.09.023
    [10]Li HaiPing, Gao Bo, Yu ZongTao, Liu JiuBo, Zhang JiCai. Significance of detection of multigene methylation in liver cancer tissue for early diagnosis of liver cancer[J]. Journal of Clinical Hepatology, 2013, 29(8): 624-626. doi: 10.3969/j.issn.1001-5256.2013.08.018
    [11]Lu: Xin, Yin Wen, Sun MengNing, Huang XiaoJun, Yang Jing, Yao Min, Xue XiaoPing, Jia ZhanSheng, Xu ZhiKai. Construction of eukaryotic expression vector of HCV CTL epitopes and establishment of stable transfected CHO cell line[J]. Journal of Clinical Hepatology, 2011, 27(1): 45-48.
    [12]Zhang JunXia, Wang Yan, Zhao YanPing, Zhang Bei, Li Jia, Huang Jian. p14ARF promoter methylation and its clinical correlation in primary liver cancer in the population of North China[J]. Journal of Clinical Hepatology, 2011, 27(10): 1051-1054.
    [13]Zhang HuiJing, Li ShengMian. Promoter methylation in APC, RASSF1A, WIF-1 gene in digestive system tumors[J]. Journal of Clinical Hepatology, 2011, 27(4): 429-432.
    [14]Xiong QiXiang, Xiong LiJuan. Hepatitis B virus infection and DNA methylation in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2011, 27(8): 881-884.
    [15]Li HongTao, Xu LiYu, Gan HongJun, Zhang YuanYuan, Liu Yong, Lu MingZhi. The expression and significance of p16 and cyclin D1 in gallbladder carcinoma[J]. Journal of Clinical Hepatology, 2010, 26(2): 199-202.
    [16]Guo XiaoLin, Jiang YaQiu, Chi BaoRong. The clinical significance of C-myc and P16 gene's expression in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2007, 23(6): 440-441.
    [19]Gu HuaPing, Liu YanRu, Shang PeiZhong. The Expression of sialyl lewis-X antigen and P16 and its relationship with biological behaviors in cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2003, 19(3): 159-160.
    [20]Meng ZhiLan, Ye DaXiong, Song XiaoHua, Yang ChunMing, Zhang Ning. P16 protein expression and DNA quantitative analysis in human hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2003, 19(3): 154-155.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(4)

    1. Muyao Zhang，Xing Wei，Zhenfei Wang. The mechanism of HBx protein to promote the initiation and progression of hepatocellular carcinoma. Infection International. 2018(01): 18-22 .
    2. 赵军，朱磊，赵国海. RNAi抑制DNA甲基转移酶1的表达对胃癌细胞p16基因的影响. 中国临床药理学与治疗学. 2018(04): 395-399 .
    3. 梁宁，郑青，张淑芳，张英爱，高丽娟. 海府地区慢性HBV感染者病毒学特征与P16mRNA改变的研究. 标记免疫分析与临床. 2017(12): 1355-1359 .
    4. 张海涛，赵晓飞，李宁，孙力波. 肝癌组织中HBV感染与甲基化转移酶表达的相关性研究. 中西医结合肝病杂志. 2017(04): 205-208 .

    Other cited types(1)

  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-0405101520
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 2.6 %FULLTEXT: 2.6 %META: 94.5 %META: 94.5 %PDF: 2.9 %PDF: 2.9 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 4.3 %其他: 4.3 %其他: 0.6 %其他: 0.6 %India: 1.2 %India: 1.2 %[]: 0.6 %[]: 0.6 %上海: 2.0 %上海: 2.0 %东京: 0.3 %东京: 0.3 %北京: 4.6 %北京: 4.6 %南宁: 0.3 %南宁: 0.3 %吉林: 1.2 %吉林: 1.2 %哥伦布: 0.3 %哥伦布: 0.3 %广州: 0.3 %广州: 0.3 %张家口: 3.7 %张家口: 3.7 %拉斯维加斯: 0.3 %拉斯维加斯: 0.3 %杭州: 0.3 %杭州: 0.3 %格兰特县: 0.3 %格兰特县: 0.3 %洛阳: 0.3 %洛阳: 0.3 %湛江: 0.3 %湛江: 0.3 %芒廷维尤: 36.0 %芒廷维尤: 36.0 %莫斯科: 1.2 %莫斯科: 1.2 %西宁: 40.1 %西宁: 40.1 %重庆: 0.3 %重庆: 0.3 %长春: 1.2 %长春: 1.2 %长治: 0.3 %长治: 0.3 %雪兰莪: 0.3 %雪兰莪: 0.3 %其他其他India[]上海东京北京南宁吉林哥伦布广州张家口拉斯维加斯杭州格兰特县洛阳湛江芒廷维尤莫斯科西宁重庆长春长治雪兰莪

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2151) PDF downloads(406) Cited by(5)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2389]YesterdayPV[5285]TodayIP[2121]TodayPV[4649]Online[48]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return